Latest Commercialization News

archTIS has reported a standout March quarter with record annual recurring revenue, improved gross margins, and strategic growth through the Direktiv acquisition and new international contracts.

Future Metals NL has confirmed significant copper-nickel-PGM mineralisation at its Eileen Bore Prospect, unveiling a newly defined 4.5km intrusion. The company also secured A$4.2 million through a placement and planned rights issue to advance development and explore strategic processing partnerships.

Opthea Limited has discontinued its wet AMD development program following Phase III trial failures, slashing its workforce by 65% amid ongoing financial uncertainty and negotiations with investors.

Novatti Group Limited has achieved a key turnaround milestone by reporting positive cash EBITDA of $100k in Q3 FY25, alongside record quarterly revenue of $13.4 million and improved margins in its core Payments AU/NZ business.

Mirvac Group reported a surge in residential sales and advanced capital partnerships for major developments, reaffirming its FY25 earnings guidance amid strong leasing and occupancy across its portfolio.

Stockland’s 3Q25 update highlights steady progress on its Waterloo Renewal Project and solid sales in masterplanned communities, supporting maintained FY25 earnings guidance.

Mad Paws Holdings Limited reported a resilient Q3 FY25 with an 8% rise in Group Cash EBITDA despite a 6% dip in operating revenue, driven by marketplace strength and a major new brand campaign.

Titomic Limited advances its strategic U.S. footprint with a new Huntsville facility set to open in June 2025, securing major defense collaborations and expanding commercial momentum in additive manufacturing.

BirdDog Technology reported a slight 4.1% decline in Q3 FY25 sales to A$3.6 million while progressing strongly on its next-generation product roadmap and implementing significant cost reductions.

Urbanise.com Limited reported steady Q3 FY2025 revenue with recurring income dominating, resolved a key contract dispute, and maintained positive operating cash flow for the third consecutive quarter.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.

Burgundy Diamond Mines reported a pivotal Q1 2025, completing the transition to Point Lake open pit mining while securing US$73 million in diamond sales and advancing mine life extension plans to 2030 and beyond.